Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1864-1871

  Hequet, O ^a   Le, Q H ^a   Moullet, I ^a   Pauli, E ^a   Salles, G ^a   Espinouse, D ^a   Dumontet, C ^a   Thieblemont, C ^a   Arnaud, P ^a   Antal, D ^a   Bouafia, F ^a   Coiffier, B ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; AGED; CHEMICALLY INDUCED DISORDER; ELECTROCARDIOGRAPHY; FRANCE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOXORUBICIN; ELECTROCARDIOGRAPHY; FEMALE; FRANCE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; RISK FACTORS;

EID: 3042698689     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.033     Document Type: Article

References (31)

1. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32:302-314, 1973
2. Lipschultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
3. Steinherz LJ, Steinherz PG, Tan CTC: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
4. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
5. Ryberg M, Nielsen D, Skovsgaard T, et al: Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508, 1998
6. Haq MM, Legha SS, Choksi J, et al: Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361-1365, 1985
7. Anderlini P, Benjamin RS, Wong FC, et al: Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13:2827-2834, 1995
8. Aviles A, Arevila A, Diaz Maqueo JC, et al: Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 11:275-279, 1993
9. Limat S, Demesmay K, Voillat L, et al: Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14:277-281, 2003
10. Ehler D, Carney DK, Dempsey AL, et al: Guidelines for cardiac sonographer education: Recommendations of the American Society of Echocardiography Sonographer Training and Education Committee. J Am Soc Echocardiogr 14: 77-84, 2001
11. Bristow MR, Mason JW, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88:168-175, 1978
12. Sorensen K, Levitt G, Bull C, et al: Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol 15:61-68, 1997
13. Friedman MA, Bozdech MJ, Billingham ME, et al: Doxorubicin cardiotoxicity: Serial endomyocardial biopsies and systolic time intervals. JAMA 240:1603-1606, 1978
14. LaMonte CS, Yeh SD, Straus DJ, et al: Long-term follow-up of cardiac function in patients with Hodgkin's treated with mediastinal irradiation and combination chemotherapy including doxorubicin. Cancer Treat Rep 70:439-444, 1986
15. Marchandise B, Schroeder E, Bosly A, et al: Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographics analysis of left ventricular filling dynamics. Am Heart J 118:92-98, 1989
16. Haddy TB, Adde MA, McCalla J, et al: Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 16:2070-2079, 1998
17. Steinhertz LJ, Wexler LH: Prevention of anthracycline cardiomyopathy. Prog Pediatr Cardiol 8:97-108, 1998
18. Hutter JJ, Sahn DJ, Woolfenden JM, et al: Evaluation of the cardiac effects of doxorubicin by serial echocardiography. Am J Dis Child 135: 653-657, 1981
19. Shan K, Lincoff M, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996
20. Steinhertz LJ, Graham T, Hurwitz R, et al: Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89:942-949, 1992
21. Kremer LCM, van der Pal HJH, Offringa M, et al: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 13:819-829, 2002
22. Mosterd A, Hoes AW, de Bruyne MC, et al: Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J 20:447-455, 1999
23. Godoy LY, Fukushige J, Igarashi H, et al: Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 39:188-193, 1997
24. Wang TJ, Levy D, Benjamin EJ, et al: The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening. Ann Intern Med 138:907-916, 2003
25. Billingham ME, Bristow MR, Glatstein E, et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17-23, 1977
26. Cazin B, Gorin NC, Laporte JP, et al: Cardiac complications after bone marrow transplantation: A report on a series of 63 consecutive transplantations. Cancer 57:2061-2069, 1986
27. Baker DW, Bahler RC, Finkelhor RS, et al: Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. Am Heart J 146:736-740, 2003
28. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
29. Lichtman SM, Niedzwiecki D, Barcos M, et al: Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: GALGB 9255-Cancer and Leukemia Group B. Ann Oncol 11:1141-1146, 2000
30. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
31. Hensley ML, Schuchter LM, Lindley C, et al: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355, 1999